- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT05886348
Utvärderingen av säkerhet och närsynthetsprogressionskontroll med hjälp av en ny glasögonlins
The goal of this clinical trial is to test Novel spectacle lenses in myopic children. The main question it aims to answer are: safety and efficacy of the lenses. Participants will be asked to wear spectacles and participate in eye exams and questionnaires. Researchers will compare Novel spectacle lenses and general single vision spectacle lenses to see if the Novel spectacle lenses correct myopic ametropia, slow the progression of myopia and axial elongation.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
This is a 3-year prospective, multicenter, randomized, and single-masked*, parallel-group controlled clinical study. The purpose of this study is to evaluate the safety and efficacy of wearing Novel spectacle lenses to correct myopic ametropia, slow the progression of myopia and axial elongation in myopic children as compared to the use of single vision spectacles lenses.
The treatment arms are:
- Model A Novel spectacle lens
- Model B Novel spectacle lens
- Single vision spectacle lens
Single-masked:
The investigator responsible for conducting ocular data measurements related to the primary and secondary endpoints will be masked. The participants will not be informed the treatment arm during the clinical trial.
Studietyp
Inskrivning (Faktisk)
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
-
Beijing, Kina
- Beijing Tongren Hospital, Capital Medical University
-
Guangzhou, Kina
- Guangzhou Aier Eye Hospital
-
Shanghai, Kina
- Eye and ENT Hospital of Fudan University
-
Shengyang, Kina
- Shengyang He Eye Specialist Hospital
-
Tianjin, Kina
- Tianjin Medical University Eye Hospital
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Participant and parent (or guardian) are able and willing to provide consent
- Participant and parent (or guardian) ensure to attend required study visits and adhere to participant requirements
- Parent or guardian understands and accepts random allocation of grouping, and that participant and parent (or guardian) will not be told which group participant is allocated to
- Participant willing to wear the study spectacles lens for a minimum of 12 hours per day for the duration of the study
- Age at time of parent or guardian consent and participant assent: 7 - 13 years old
- Spherical equivalent cycloplegic autorefraction: -1.00 to -7.00 D in each eye.
- Cycloplegic autorefraction astigmatism of 1.50 D or less in each eye
- Cycloplegic autorefraction anisometropia of 1.50 D or less
- Monocular best corrected distance visual acuity (BCDVA) equal to or better than logMAR 0.10 in each eye.
Exclusion Criteria:
- Participant is allergy to fluorescein, benoxinate, proparacaine, tropicamide or cyclopentolate eye drops
- Any ocular and systemic abnormalities might be expected to affect visual functions or refractive development
- (a) Have received treatment of myopic control pharmaceutical medication (e.g., atropine) or light fundus illuminance therapy (e.g., repeated red light therapy) within 6 months prior to entry into this study. (b) Have received treatment of myopia control such as contact lenses, orthokeratology lenses etc., progressive addition lenses, bifocal lenses, within 3 months. (c) Have received treatment of myopia control such as defocus spectacle lenses (difference between both eye's non-cycloplegic autorefraction and lens-meter results of the respective lenses are equal or less than 0.50 D SER) etc. within one month prior to entry into this study.
- Participant with clinically significant strabismus (including intermittent tropia)
- Medical history of binocular vision abnormalities
- Participant with amblyopia
- Participation in a clinical trial within 30 days prior to entry into this study or during participation
- Previous intraocular surgery
- Participant who, in the judgment of the Investigator, presence of any emotional, physiologic, or anatomical condition which may preclude participation in this study or provide an inappropriate landscape for the intended study treatment.
- Any medical treatment or medication which might have an influence on vision or interfere with study assessments
- Pathological myopia (myopia that leads to structural changes in the posterior segment of the eye including posterior staphyloma, myopic maculopathy, and high myopia-associated optic neuropathy)
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Enda
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Model-A Novel Glasögonlins
|
Model-A Novel spectacle lenses will be given to 1 arm to wear for 36 months |
|
Experimentell: Model-B Novel Glasögonlins
|
Model-B Novel spectacle lenses will be given to 1 arm to wear for 36 months |
|
Övrig: Single Vision glasögonlins
|
Single Vision Spectacle lenses will be given to 1 arm to wear for 36 months |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Axial length
Tidsram: 24 months
|
The difference of Axial length changes over 24 months between treatment groups in low and moderate myopia (-1.00 D to -5.00 D) participants. |
24 months
|
|
Spherical equivalent cycloplegic autorefraction
Tidsram: 24 months
|
The difference of spherical equivalent cycloplegic autorefraction changes over 24 months between treatment groups in low and moderate myopia (-1.00 D to -5.00 D) participants |
24 months
|
Sekundära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Axiell längd
Tidsram: 36 månader
|
36 månader
|
|
Sfärisk ekvivalent cykloplegisk autorefraktion
Tidsram: 36 månader
|
36 månader
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- DG2-3A
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .